New Age Alpha Advisors LLC Buys Shares of 3,007 Glaukos Co. (NYSE:GKOS)

New Age Alpha Advisors LLC acquired a new stake in Glaukos Co. (NYSE:GKOS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 3,007 shares of the medical instruments supplier's stock, valued at approximately $451,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GKOS. BNP Paribas Financial Markets raised its holdings in shares of Glaukos by 186.9% during the third quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier's stock valued at $1,788,000 after buying an additional 8,942 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in Glaukos in the 4th quarter valued at approximately $3,679,000. State Street Corp raised its stake in Glaukos by 5.3% during the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier's stock valued at $254,626,000 after acquiring an additional 98,109 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in Glaukos during the 3rd quarter worth $258,000. Finally, Rhumbline Advisers grew its stake in shares of Glaukos by 0.3% in the fourth quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier's stock worth $21,260,000 after purchasing an additional 403 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Trading Down 3.9 %

GKOS stock traded down $3.38 during mid-day trading on Friday, reaching $83.62. 1,715,189 shares of the stock traded hands, compared to its average volume of 616,738. Glaukos Co. has a 52-week low of $77.91 and a 52-week high of $163.71. The stock's fifty day moving average is $123.88 and its 200-day moving average is $134.70. The company has a market cap of $4.73 billion, a P/E ratio of -29.14 and a beta of 0.99. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Remove Ads

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $105.50 million during the quarter, compared to analysts' expectations of $100.72 million. As a group, sell-side analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Insider Activity

In related news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on GKOS. Citigroup raised shares of Glaukos from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Piper Sandler reiterated an "overweight" rating and issued a $180.00 price objective (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Stifel Nicolaus upped their target price on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Truist Financial lifted their price target on Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Finally, Wells Fargo & Company upped their price objective on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $163.25.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.